The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma.
 
Aiwu Ruth He
No Relationships to Disclose
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Genentech/Roche; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Genentech/Roche; Novartis; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)
 
Renuka V. Iyer
No Relationships to Disclose
 
Davendra Sohal
Research Funding - Bayer (Inst); Celgene (Inst); Genentech (Inst); Novartis (Inst); OncoMed (Inst)
Travel, Accommodations, Expenses - Foundation Medicine
 
Hongkun Wang
No Relationships to Disclose
 
Karen Dorsch-Vogel
No Relationships to Disclose
 
Michael J. Pishvaian
No Relationships to Disclose
 
Mohamed E. Salem
No Relationships to Disclose
 
Brandon George Smaglo
No Relationships to Disclose
 
John Marshall
No Relationships to Disclose